DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Posição atual:
>
> This Story


Início de uma sessão ou Registo to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Rad Oncology Homepage

Varian acquires CyberHeart, enters cardiac radioablation market Emerging technology could benefit treatment of irregular heartbeats

New 12-year study highlights value of PRRT, based on long-term outcomes Understanding peptide receptor radionuclide therapy

Korean cancer center aims to deploy heavy ion therapy in 2022 Plans also call for the onboarding of more CR and MR systems

RefleXion Medical secures $60 million for approval and launch of BgRT system Can detect and treat multiple tumors in the same session

Radiation oncologists appeal to Congress to safeguard radiotherapy treatment Protecting cancer patients' access to value-based care

Using ERISA to end proton therapy denials Insights from Timothy J. Rozelle and Lisa S. Kantor, from Kantor & Kantor, LLP on getting insurers to provide coverage

Philips unveils IntelliSpace Radiation Oncology system at ESTRO Manages complexity and efficiency of radiology departments

Elekta sues ZAP Surgical Systems, claiming patent infringement Over design and sale of ZAP's radiosurgery platform

Studies unveil measures for reducing resistance to radiotherapy in tumors Stimulates immune system to attack cancer cells

Fivefold difference found in Medicaid reimbursements for radiotherapy May limit access to healthcare, especially in rural areas

Precision-based medicine improves outcomes and drives down costs

From the June 2017 issue of DOTmed HealthCare Business News magazine

Insurers may be more apt to approve precision medicine techniques when considering a cost-benefit analysis. For cancer patients, expenses will drop as they receive targeted medication within days of diagnosis, and are able to skip more toxic treatments that result in hospitalization, intravenous lines, complications of those, steroids and other medication to lessen side effects and nursing. For example, a report by PricewaterhouseCoopers indicates that a genetic test on breast cancer patients could save an estimated $1,900 per patient because it can reduce chemotherapy use between 20 and 35 percent. Likewise, increased diagnostic accuracy for cancer screenings will reduce the costs and morbidity associated with false positive tests.

In hospitals, where insurance reimbursement rates depend upon patient experience and satisfaction, and expenditures are always closely monitored, precision medicine is already improving outcomes. In one study, precision medicine was shown to reduce readmissions by 52 percent, reduce visits to the emergency department by 42 percent and decrease deaths by 85 percent. Hospitals have a responsibility to their patients (and shareholders) to proactively promote new advancements in medicine. They should utilize their considerable clout to support research and development companies during FDA trials to ensure their physicians have access to the latest precision therapies once approved.
Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED




With the passage of the 21st Century Cures Act, precision medicine has received the backing of the U.S. government. The bill, which provides $4.8 billion in funding to initiatives aimed at matching patients to treatments based on their genes, signals a shift toward creating new health care standards. With the ability to fund more genetic sequencing, it is my hope that we can develop new treatment and diagnostic approaches for a wide range of cancers.

About the author:
Paul Crowe is chairman and CEO of Nuview Life Sciences. Crowe is an experienced health care executive who, over the past 40 years, participated in the commercialization of new diagnostic imaging technologies such as diagnostic ultrasound, magnetic resonance imaging and positron emission tomography (PET). These technologies provided physicians with better tools to more effectively diagnose, and subsequently treat, chronic human diseases, improved patient outcomes and lowered health care costs.

Back to HCB News
<< Pages: 1 - 2

Rad Oncology Homepage


You Must Be Logged In To Post A Comment

Anuncie
Aumente a Sua Perceção da Marca
Leilões + Vendas Privadas
Comece
O mais melhor preço
Comprar Equipamento/Peças
Encontre
O preço o mais baixo
Notícia diária
Leia
A notícia a mais atrasada
Diretório
Browse tudo
DOTmed Usuários
Ética no DOTmed
Veja o nosso
Programa das éticas
O ouro parte o programa do vendedor
Receba PH
Pedidos
Programa do negociante do serviço do ouro
Receba RFP/PS
Pedidos
Fornecedores de Healthcare
Veja tudo
Ferramentas de HCP
Trabalhos/Treinamento
Achado/suficiência
Um trabalho
Parts Hunter +EasyPay
Comece as peças
Citações
Certificado recentemente
Vista recentemente
Usuários certificados
Recentemente Rated
Vista recentemente
Usuários certificados
Central Rental
Equipamento do aluguel
Para menos
Vender Equipamentos/Peças
Comece
A maioria de dinheiro
Preste serviços de manutenção ao Forum dos técnicos
Ajuda do achado
E conselho
Simples RFP
Comece o equipamento
Citações
Mostra de comércio virtual
Serviço do achado
Para o equipamento
O acesso e o uso deste local são sujeitos aos termos e às condições do nosso OBSERVAÇÃO LEGAL & OBSERVAÇÃO DA PRIVACIDADE
Propriedade de e proprietário DOTmeda .com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
TODOS OS DIREITOS RESERVADOS